Anavex Life Sciences (AVXL) Assets Average (2012 - 2025)
Anavex Life Sciences recorded quarterly Assets Average of $118.4 million in Q4 2025, up 14.82% quarter-over-quarter from $103.1 million in Q3 2025, and down 8.78% year-over-year from $129.8 million in Q4 2024.
Anavex Life Sciences' Assets Average history runs 13 years deep, the most recent figure standing at $118.4 million for Q4 2025.
- In Q4 2025, Assets Average fell 8.78% year-over-year to $118.4 million; the TTM figure through Dec 2025 stood at $118.4 million (down 8.78% YoY), while the FY2025 annual figure was $119.7 million, down 17.44% from the prior year.
- Assets Average came in at $118.4 million for Q4 2025 at Anavex Life Sciences, up from $103.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $164.0 million in Q3 2021 to a low of $69.0 million in Q1 2021.
- A 5-year average of $138.6 million and a median of $148.4 million in 2022 frame the typical range for Assets Average.
- Across the five-year window, Assets Average soared 395.73% in 2021 and dropped 25.57% in 2025, its largest moves.
- Anavex Life Sciences' Assets Average stood at $159.3 million in 2021, then declined by 5.47% to $150.5 million in 2022, then climbed by 0.46% to $151.2 million in 2023, then fell by 14.17% to $129.8 million in 2024, then slipped by 8.78% to $118.4 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $118.4 million, $103.1 million, and $109.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 118.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 118.40 Mn |
| Sep 30, 2025 | 103.12 Mn |
| Jun 30, 2025 | 109.79 Mn |
| Mar 31, 2025 | 120.59 Mn |
| Dec 31, 2024 | 129.81 Mn |
| Sep 30, 2024 | 138.55 Mn |
| Jun 30, 2024 | 143.03 Mn |
| Mar 31, 2024 | 146.29 Mn |
| Dec 31, 2023 | 151.23 Mn |
| Sep 30, 2023 | 156.10 Mn |
| Jun 30, 2023 | 158.50 Mn |
| Mar 31, 2023 | 153.78 Mn |
| Dec 31, 2022 | 150.54 Mn |
| Sep 30, 2022 | 156.46 Mn |
| Jun 30, 2022 | 160.25 Mn |
| Mar 31, 2022 | 158.59 Mn |
| Dec 31, 2021 | 159.26 Mn |
| Sep 30, 2021 | 164.02 Mn |
| Jun 30, 2021 | 125.00 Mn |
| Mar 31, 2021 | 68.95 Mn |
| Dec 31, 2020 | 44.44 Mn |
| Sep 30, 2020 | 33.09 Mn |
| Jun 30, 2020 | 31.33 Mn |
| Mar 31, 2020 | 31.22 Mn |
| Dec 31, 2019 | 28.38 Mn |
| Sep 30, 2019 | 23.65 Mn |
| Jun 30, 2019 | 21.26 Mn |
| Mar 31, 2019 | 21.32 Mn |
| Dec 31, 2018 | 24.15 Mn |
| Sep 30, 2018 | 26.50 Mn |
| Jun 30, 2018 | 26.35 Mn |
| Mar 31, 2018 | 27.12 Mn |
| Dec 31, 2017 | 28.09 Mn |
| Sep 30, 2017 | 26.37 Mn |
| Jun 30, 2015 | 7.17 Mn |
| Mar 31, 2015 | 6.71 Mn |
| Dec 31, 2014 | 7.20 Mn |
| Sep 30, 2014 | 8.33 Mn |
| Jun 30, 2014 | 9.80 Mn |
| Mar 31, 2014 | 5.22 Mn |
| Dec 31, 2013 | 272,168.00 |
| Sep 30, 2013 | 198,464.50 |
| Jun 30, 2013 | 1,983.50 |
| Mar 31, 2013 | 40,193.50 |
| Dec 31, 2012 | 46,526.50 |
| Sep 30, 2012 | 17,644.00 |
| Jun 30, 2012 | 106,617.50 |